A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-12-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-03-339879PMID 21911830
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

  2013cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.

  2011cited by this paper
• A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

  2011influential reference
• Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

  2011cited by this paper
• Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

  2011cited by this paper
• Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

  2011cited by this paper
• Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

  2010influential reference
• The DAC system and associations with multiple myeloma

  2010cited by this paper
• Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

  2010cited by this paper
• Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.

  2010cited by this paper
• Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

  2010cited by this paper
• Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression.

  2010cited by this paper
• Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

  2010cited by this paper
• A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

  2010influential reference
• NF-kappaB-induced chromatin remodeling regulates angiogenesis.

  2010cited by this paper
• Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

  2009cited by this paper
• Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin.

  2009cited by this paper
• Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

  2009cited by this paper
• Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

  2008cited by this paper
• Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

  2008influential reference
• A Phase II Multiple Dose Clinical Trial of Histone Deacetylase Inhibitor ITF2357 in Patients with Relapsed or Progressive Multiple Myeloma: Preliminary Results.

  2007cited by this paper
• Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

  2007cited by this paper
• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.

  2006influential reference
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

  2006cited by this paper
• Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

  2005influential reference
• A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors

  2004cited by this paper
• Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

  2004cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004influential reference
• Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

  2004cited by this paper
• A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

  2004cited by this paper
• Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003influential reference
• Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• Accelerated titration designs for phase I clinical trials in oncology.

  1997cited by this paper
• Heat shock, stress proteins, chaperones, and proteotoxicity.

  1991influential reference
• Multiple myeloma.

  1948influential reference

• Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targets.

  2025cites this paper
• Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy.

  2024cites this paper
• Histone deacetylase inhibitors for leukemia treatment: current status and future directions

  2024cites this paper
• HDAC inhibitors: Promising agents for leukemia treatment.

  2023cites this paper
• Histone deacetylase‐based dual targeted inhibition in multiple myeloma

  2023cites this paper
• Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

  2021cites this paper
• Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

  2020cites this paper
• Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.

  2020cites this paper
• A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

  2019cites this paper
• The biological significance of histone modifiers in multiple myeloma: clinical applications

  2018cites this paper
• A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

  2017cites this paper
• Romidepsin induces caspase-dependent cell death in human neuroblastoma cells.

  2017cites this paper
• New Agents in Multiple Myeloma: An Examination of Safety Profiles

  2017influential citation
• Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

  2017cites this paper
• Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma

  2017cites this paper
• How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

  2017cites this paper
• Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

  2016cites this paper
• Use of class I histone deacetylase inhibitor romidepsin in combination regimens

  2016influential citation
• Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma

  2016cites this paper
• Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma

  2016cites this paper
• Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

  2016cites this paper
• Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

  2016cites this paper
• Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

  2016cites this paper
• The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.

  2016cites this paper
• Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

  2016cites this paper
• Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.

  2016cites this paper
• Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

  2015cites this paper
• Cyclic depsipeptides as potential cancer therapeutics.

  2015cites this paper
• Epigenetics and Epigenetic Therapy of Cancer

  2015cites this paper
• Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

  2015cites this paper
• Romidepsin for the treatment of non-Hodgkin’s lymphoma

  2015cites this paper
• MiR-29 b replacement inhibits proteasomes and disrupts aggresome + autophagosome formation to enhance the antimyeloma bene fi t of bortezomib

  2015cites this paper
• Targeting Histone Deacetylases in Diseases: Where Are We?

  2015cites this paper
• Panobinostat for the treatment of multiple myeloma

  2015cites this paper
• Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review

  2015cites this paper
• Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat

  2015cites this paper
• Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

  2015cites this paper
• Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

  2014cites this paper
• New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

  2014cites this paper
• MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib

  2014cites this paper
• Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia

  2014cites this paper
• Epigenetic therapy of cancer with histone deacetylase inhibitors.

  2014cites this paper
• Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model

  2014cites this paper
• The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

  2014cites this paper
• Hypoxia-regulated gene network in drug resistance and cancer progression

  2014cites this paper
• [New drugs in the treatment of multiple myeloma].

  2014cites this paper
• Current and potential epigenetic targets in multiple myeloma.

  2014cites this paper
• The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

  2014cites this paper
• Resistance to Proteasome Inhibitors in Multiple Myeloma

  2014cites this paper
• Improving the outcome of patients with lymphoproliferative disorders

  2014cites this paper
• Resistance of Multiple Myeloma to Proteasome Inhibitors

  2014cites this paper
• Novel Agents in Multiple Myeloma

  2013cites this paper
• Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

  2013cites this paper
• Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

  2013cites this paper
• Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches

  2013cites this paper
• Romidepsin for the treatment of T-cell lymphomas.

  2013cites this paper
• Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

  2013cites this paper
• The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases*

  2013cites this paper
• Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC

  2013cites this paper
• Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

  2013cites this paper
• Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.

  2013cites this paper
• Current Epigenetic Therapy for T-Cell Lymphoma

  2013cites this paper
• Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding

  2013cites this paper
• Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

  2013cites this paper
• Histone Deacetylase Inhibitors as Targeted Therapies

  2013cites this paper
• Histone Deacetylase Inhibitors, Oxidative Stress, and Multiple Myeloma Therapy

  2012cites this paper
• Bortezomib combination therapy in multiple myeloma.

  2012cites this paper
• Histone deacetylase inhibitors and rational combination therapies.

  2012cites this paper
• Chemotherapy-Induced Neuropathic Pain

  2012cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies

  2012cites this paper
• M(yeloma)IXing up T maintenance.

  2012cites this paper
• Panobinostat for the treatment of multiple myeloma

  2012cites this paper
• HDAC modulation and cell death in the clinic.

  2012cites this paper
• New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

  2012cites this paper
• Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.

  2012cites this paper
• A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

  2012cites this paper
• Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials

  2012cites this paper
• Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.

  2012cites this paper
• From the observation DAC: romidepsin revisited.

  2011cites this paper
• World Journal of Diabetes

  year unknowncites this paper